Pennymac, UWM, loanDepot lag in RMBS issuance as Rocket grabs share

BTIG reports Pennymac, UWM, and loanDepot's Q3 agency MBS issuance lagged estimates, while Rocket and Onity exceeded expectations. Industry-wide MBS issuance fell 4% in September, with non-QM issuance down 18% QoQ but up 6% YoY. BTIG revised 2023 and 2024 origination forecasts downward, citing elevated mortgage rates and seasonal slowdowns.

Original reporting
Published Oct 2, 2026, 8:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 11:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pennymac, UWM, loanDepot lag in RMBS issuance as Rocket grabs share — source image
Decision brief

The 30-second read

$PMTBearishLow
01

Why it matters

The report provides fresh data on issuance performance, a key leading indicator for mortgage lenders.

02

Market read

Issuance shortfalls signal weaker loan pipelines, affecting earnings outlooks for major U.S. mortgage lenders.

03

What to watch

Potential boost from home‑equity lending at loanDepot and upcoming Mr. Cooper integration at Rocket.

Relevance 4/10Novelty 3/10Timing: today

Background

BTIG's latest Mortgage Originators report compares third‑quarter RMBS issuance against internal and consensus forecasts, highlighting sector‑wide slowdown.

Company-level read

Ticker impact

$PMTBearishHigh confidence
Context

Pennymac's RMBS issuance fell far below BTIG estimates, losing about 500 bps of market share.

Expected impact

potential decline as investors price in lower loan volume and market‑share loss

Evidence & confidence

BTIG report highlights a material miss versus expectations, which typically drags the stock.

$RCKTBullishHigh confidence
Context

Rocket Companies posted a 10.5% market share of retail purchase MBS issuance in September, up 110 bps from August.

Expected impact

upward pressure as market rewards higher share gains

Evidence & confidence

Rocket's strong issuance performance contrasts with peers and may boost valuation multiples.

Market effects

Mortgage‑backed securities issuance weakness may weigh on the broader mortgage‑lender sector.

U.S. mortgage originators could see tighter spreads and lower loan volumes.

Limited to U.S. housing finance; minimal direct global spillover.

Counterpoint

If interest‑rate volatility stabilizes, the issuance miss may be temporary and stocks could rebound.

Key entities

  • BTIG

    Provides mortgage‑originator coverage and issuance forecasts.

Related articles

$RCKTMedAI 8/10

Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility

Rocket Pharmaceuticals (RCKT) shares rose 4% after securing a $150M credit facility with Hercules Capital. The funding supports its Phase 2 study of RP-A501 for Danon disease and its cardiovascular pipeline. Early safety data from the first three patients treated under a modified protocol showed no evidence of thrombotic microangiopathy or capillary leak syndrome. The company expects to complete the trial by mid-2027 and report results in mid-2028.

$RCKTHighAI 8/10

Hercules Capital Provides Up to $150MM Strategic Credit Facility to Rocket Pharmaceuticals - News

Rocket Pharmaceuticals secured a $150M credit facility from Hercules Capital to support its cardiovascular pipeline, including a Phase 2 study for Danon disease. The facility provides up to $35M initially, with additional funds tied to milestones. Rocket expects current resources to fund operations into Q3 2028, extendable to 2029 with further borrowings.

$RCKTMedAI 8/10

Rocket Pharma outlines path for Danon disease gene therapy

Rocket Pharmaceuticals (RCKT) presented Phase 2 trial details for its Danon disease gene therapy, RP-A501. The trial aims to enroll 12 male patients, with success criteria including myocardial LAMP2 protein expression and a 10% reduction in left ventricular mass index. Preliminary data showed no immediate safety concerns. The company estimates the U.S. Danon disease population at 10,000-11,000, with a focus on males. Trial completion is expected by mid-2027, with results in mid-2028.